<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452451</url>
  </required_header>
  <id_info>
    <org_study_id>HM-EXC-202</org_study_id>
    <nct_id>NCT01452451</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Double-Masked, Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 2 Study to Determine the Tolerability, Pharmacokinetics, and Pharmacodynamics of the GLP 1 Agonist HM11260C in Adult Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of repeated doses of
      HM11260C when given different regimens in subjects with type 2 diabetes mellitus (T2DM) on
      stable metformin monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 106 days</time_frame>
    <description>Number of subjects with adverse events as a measure of safety and tolerability when given different regimens to subjects in T2DM with metformin monotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetics in repeat-dose</measure>
    <time_frame>Day 1 up to Day 92</time_frame>
    <description>Before dosing on the first dosing day (Day 1)
After the first dose: 8, 24, 48, 72, 96, 120, and 144 hours after dosing
Trough samples (ie, immediately before dosing) will be taken prior to dosing on Days 8, 22, 36, 57, 71, and 85
After the last dose (thirteenth dose) at 8, 24, 48, 72, 96, 120, and 144 hours after dosing and 7, 10, 14, 21, 28, and 35 days after dosing to define the elimination period of HM11260C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacodynamics in repeat-dose</measure>
    <time_frame>Up to 106 days</time_frame>
    <description>HbA1c, glycosylated albumin, fructosamine, insulin, and fasting glucose: For all cohorts: screening; Day -1; before dosing on Days 29, 57, and 85; and at follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HM11260C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HM11260C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM11260C</intervention_name>
    <description>1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3</description>
    <arm_group_label>HM11260C</arm_group_label>
    <other_name>LAPS-Exendin4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is male or female and 18 to 65 years of age, inclusive, at screening

          -  Has a history of T2DM and a stable dose of metformin

          -  Has HbA1c levels at screening between 7% and 10%

        Exclusion Criteria:

          -  Is pregnant or lactating

          -  Has type 1 diabetes

          -  Has a significant change in body weight in the 3 months before screening

          -  Has a fasting plasma glucose level greater than 240 mg/dL (13.3 mmol/L) at screening

          -  Has an estimated glomerular filtration rate rate &lt;75 mL/min/1.73 m2 or has ≥75
             mL/min/1.73 m2 &lt;estimated glomerular filtration rate &lt;90 mL/min/1.73 m2 with a urine
             albumin to urine creatinine ratio &gt;30 mg/g.

          -  Has alanine aminotransferase or aspartate aminotransferase values &gt;2.0 × upper limit
             of normal or total bilirubin &gt;1.5 × upper limit of normal unless the subject has a
             known history of Gilbert's syndrome

          -  Has fasting serum triglycerides &gt;400 mg/dL (&gt;4.52 mmol/L) or &gt;250 mg/dL (&gt;2.85 mmol/L)
             if not on stable lipid-lowering therapy for at least 4 weeks prior to screening, or
             has calcitonin ≥50 ng/L. Subjects with a history of Fredrickson's Type I, IV or V
             hyperlipidemia will be excluded.

          -  Has any history of GI intolerance, chronic diarrhea, inflammatory bowel disease,
             partial bypass or gastric banding

          -  Has any acute illness within 5 days before first study drug administration

          -  Has elevated amylase, ongoing cholelithiasis, cholecystitis at screening, or history
             of pancreatitis

          -  Is a heavy tobacco user(more than 10 cigarettes a day)

          -  Is a heavy alcohol user

          -  Has a positive screen for drugs of abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Ohio</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <disposition_first_submitted>August 8, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>August 8, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 9, 2016</disposition_first_posted>
  <last_update_submitted>August 8, 2016</last_update_submitted>
  <last_update_submitted_qc>August 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

